Tus Pharmaceutical Group Co Ltd - Asset Resilience Ratio
Tus Pharmaceutical Group Co Ltd (000590) has an Asset Resilience Ratio of 4.91% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Tus Pharmaceutical Group Co Ltd (000590) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2022)
This chart shows how Tus Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Tus Pharmaceutical Group Co Ltd to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Tus Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Tus Pharmaceutical Group Co Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥43.00 Million | 4.91% |
| Total Liquid Assets | CN¥43.00 Million | 4.91% |
Asset Resilience Insights
- Limited Liquidity: Tus Pharmaceutical Group Co Ltd maintains only 4.91% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tus Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tus Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Tus Pharmaceutical Group Co Ltd (2002–2022)
The table below shows the annual Asset Resilience Ratio data for Tus Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 2.15% | CN¥25.11 Million ≈ $3.67 Million |
CN¥1.17 Billion ≈ $170.73 Million |
-5.61pp |
| 2021-12-31 | 7.76% | CN¥75.15 Million ≈ $11.00 Million |
CN¥967.83 Million ≈ $141.62 Million |
-14.35pp |
| 2017-12-31 | 22.12% | CN¥193.23 Million ≈ $28.28 Million |
CN¥873.74 Million ≈ $127.86 Million |
+18.69pp |
| 2014-12-31 | 3.42% | CN¥20.09 Million ≈ $2.94 Million |
CN¥586.82 Million ≈ $85.87 Million |
+3.41pp |
| 2006-12-31 | 0.02% | CN¥85.15K ≈ $12.46K |
CN¥545.36 Million ≈ $79.80 Million |
+0.00pp |
| 2005-12-31 | 0.01% | CN¥93.07K ≈ $13.62K |
CN¥664.58 Million ≈ $97.25 Million |
0.00pp |
| 2004-12-31 | 0.01% | CN¥96.04K ≈ $14.05K |
CN¥676.63 Million ≈ $99.01 Million |
0.00pp |
| 2003-12-31 | 0.02% | CN¥130.61K ≈ $19.11K |
CN¥685.16 Million ≈ $100.26 Million |
-0.01pp |
| 2002-12-31 | 0.02% | CN¥180.63K ≈ $26.43K |
CN¥724.86 Million ≈ $106.07 Million |
-- |
About Tus Pharmaceutical Group Co Ltd
Guhan Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells traditional Chinese medicines, chemical drugs, and health food under the Guhan brand in China. It operates through the Pharmaceutical and Health Product Manufacturing and Sales Business, Active Pharmaceutical Ingredient (API) Manufacturing and Sales Business, and Other Business segments. The company offer… Read more